<DOC>
	<DOCNO>NCT00225810</DOCNO>
	<brief_summary>The primary objective clinical trial assessment acceptability new Pentasa formulation - PentasaR Sachets comparison reference PentasaR tablets 500 mg child Crohn 's disease . After screen period ( include medical history , physical examination , basic haematology , serum chemistry , urine analysis stool microbiology , PCD Activity Index ) patient receive ( visit I ) Pentasa sachets 1g Pentasa tablet 500mg next 4 week accord randomisation scheme common dose 2× 1 g PentasaR Sachets 1 g PentasaR tablets 500 mg . The formulation Pentasa switch Visit 2 , patient receive medication next 4 week . Patients record acceptability form medication . In 6 patient group ( select randomization ) , stool urine take assess concentration mesalazine N-acetylmesalazine Visit 2 Visit 3 . Adverse event record whole course treatment period .</brief_summary>
	<brief_title>A Study Comparing Acceptability Pentasa® Sachets Versus Pentasa® Tablets Children With Crohn´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Established diagnose Crohn 's disease Age 818 year , sex Weight 40 kg Oral maintenance treatment 5ASA concomitant antinflammatory medication ( maintain dose study ) inclusion permit , write informed consent obtain ( patient his/her guardian ) Patients history allergy salicylates Patients know significant hepatic renal function abnormality Positive enteric pathogen stool ( Salmonella , Shigella , Yersinia , Campylobacter ) Pregnant lactate woman Patients known history disease , include mental/emotional disorder , would interfere participation study , Patients participate another clinical study last 3 month , Patients unable comply requirement protocol Patients unable fill diary card</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>